Sir,
The human Ether-à-go-Related Gene (hERG) encodes potassium channels mediating the rapid delayed-rectifier K⁺ current, IᵩKr, which is crucial for normal repolarization of the ventricles of the heart.¹ hERG is established to be a pharmacological target for Class Ia and Class III antiarrhythmic drugs and for numerous noncardiac drugs associated with acquired long QT syndrome and torsades de pointes arrhythmia.¹ Due to the pharmacological promiscuity of hERG channels, all novel pharmaceuticals must be tested for their propensity to inhibit hERG channel ionic current.¹

The archetypal high-affinity hERG inhibitors come from the methanesulphonanilide drug family.¹,² This family includes dofetilide (Tikosyn), a drug licensed in the USA for the treatment of supraventricular arrhythmias and an experimental Class III drug, E-4031 [Figure 1A]. Sotalol [Figure 1A], which is used to treat both supraventricular arrhythmias and serious ventricular arrhythmias in structurally normal hearts, differs from other methanesulphonanilides in that it binds with low affinity to hERG/IᵩKr channels. For example, a study of displacement of tritiated dofetilide by E-4031, dofetilide, and D-sotalol from guinea-pig ventricular myocytes yielded respective Kᵩ values of 38 nM, 47 nM, and 100 µM.³ The structural basis for sotalol’s low-affinity hERG/IᵩKr block has not yet been established. Binding determinants of E-4031 and dofetilide, as well as another high-affinity methanesulphonanilide, MK499, have been mapped to the S6- and pore-helices that form the inner cavity of the hERG channel;²,⁴ mutation of S6 aromatic residues (Y652 and F656) and of residues at the base of the pore helix (T623, S624, V625) markedly impaired the ability of these drugs to inhibit hERG current (IᵩKr).²,⁴ Comparable information is not currently available for sotalol, perhaps in part due to difficulties in obtaining pure D-sotalol (which lacks the marked β-adrenoceptor-blocking properties of the racemic mixture) and in part because the low potency of the drug makes it difficult to study at concentrations required to produce profound IᵩKr inhibition.

Comparison of the structures of E-4031 and dofetilide with sotalol [Figure 1A] shows that sotalol is a smaller molecule than the other drugs. We have previously compared structurally similar hERG-blocking drugs of different sizes (ranolazine and lidocaine) and found that, despite structural similarities, the smaller drug (lidocaine) was less well able to interact with hERG pore side chains than the larger molecule.³ We hypothesized that a similar explanation accounts for relatively low-affinity IᵩKr block by sotalol. Accordingly, using a previously validated, MthK-based hERG pore model,⁵ we have docked D-sotalol in the hERG channel inner cavity [Figure 1Bi and Bii]. Low-energy-score binding poses show an ability for sotalol to interact with the aromatic canonical drug-binding residues Y652 and F656. The charged secondary aliphatic amino group and aromatic moiety of D-sotalol can make cation-π and π-stacking interactions, respectively, with the side chains of F656 or Y652. In these poses, D-sotalol does not make simultaneous interactions with pore-helical residues T623 or S624.

Figure 1: (A) Chemical structures of sotalol, dofetilide, and E-4031 generated using Symyx® Draw 3.3. (Bi) Low-energy score binding pose in the context of the whole channel pore. D-sotalol is shown as a space-filling structure colored according to atom type. The pore tetramer is represented by a green ribbon, and K⁺ ions occupy the S1 and S3 positions of the selectivity filter. Side chains of T623 and S624 (green), Y652 (pink), and F656 (blue) are displayed as sticks. (Bii) The same binding mode focusing on the side chains of amino acids lining the pore interior known to be determinants of high-potency methanesulphonanilide block. The charged secondary aliphatic amino group and aromatic moiety of D-sotalol can make cation-π and π-stacking interactions, respectively, with the side chains of F656 (blue) or Y652 (pink). In these poses, D-sotalol does not make simultaneous interactions with pore-helical residues T623 or S624.
Figure 2: (Ai-iii) Representative traces of $I_{\text{HERG}}$ in control solution and following exposure to 100 $\mu$M D-sotalol (Ai) shows data for wild-type $I_{\text{HERG}}$ (Ai) for S624A $I_{\text{HERG}}$ (Aii) for Y652A $I_{\text{HERG}}$. The corresponding voltage protocol is shown in (B). (C) Bar charts showing the mean (± standard error of the mean) levels of inhibition (shown as fractional block) produced by 100 $\mu$M D-sotalol for wild-type, S624A, and Y652A hERG. Numbers of replicates (5–7) are given in brackets. There was no significant difference between wild-type (mean fractional block of 0.53) and S624A (mean fractional block of 0.47; $P > 0.05$), but Y652A (mean fractional block of 0.27) showed significantly attenuated inhibition ($** P < 0.001$); one-way analysis of variance with Bonferroni post-test. Recordings made at 37°C with K-based pipette solution and standard external Tyrode’s solution.$^{[10]}$ $I_{\text{HERG}}$: Ionic current carried by human Ether-à-go-go-Related Gene (hERG) channels.

Figure 2B.$^{[5]}$ D-sotalol was obtained from Sequal Research Products. Electrophysiological properties of the S624A and Y652A mutants allow them to be studied under identical conditions to the WT channel. 100 $\mu$M D-sotalol blocked WT $I_{\text{HERG}}$ by ~53% [Figure 2Ai and 2C], and this was not significantly reduced for S624A $I_{\text{HERG}}$ [Figure 2Aii and 2C]. In contrast, the Y652A mutation produced a moderate, statistically significant attenuation of $I_{\text{HERG}}$ block by D-sotalol [Figure 2Aii and 2C].

Our results support the notion that the smaller size of sotalol than of other methanesulphonanilides limits its ability to make simultaneous contacts with aromatic and pore-helix residues and that this, together with weaker contacts with key-binding determinants, underpins its low-affinity $I_{\text{HERG}}$ block. We suggest that a future detailed alanine scan of the inner cavity would be valuable to define more precisely the sotalol interaction site(s) on the hERG channel.

**Financial support and sponsorship**
The authors gratefully acknowledge the British Heart Foundation for funding (PG/10/017; PG/12/; PG/12/69/29784; PG/14/61/31015).

**Conflicts of interest**
There are no conflicts of interest.

**REFERENCES**


This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 license, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**Access this article online**

Quick Response Code:

Website: www.jpharmacol.com

DOI: 10.4103/jpp.JPP_69_17

How to cite this article: Zhang YH, Dempsey CE, Hancox JC. The basis for low-affinity hERG potassium channel block by sotalol. J Pharmacol Pharmacother 2017;8:130-1.

Received: 18-05-2017 Revised: 03-07-2017 Accepted: 09-08-2017

© 2017 Journal of Pharmacology and Pharmacotherapeutics | Published by Wolters Kluwer - Medknow